The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a SMARCA4 mutation.
 
Timothy Yap
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - 858 Therapeutics; Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amgen; Amphista Therapeutics; Artios; Astex Pharmaceuticals; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avenzo Therapeutics; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; BioCity; Bloom Burton; Blueprint Medicines; Boxer Capital; BridGene Biosciences; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Carrick Therapeutics; Chinese University of Hong Kong; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Daiichi Sankyo; Dark Blue Therapeutics; Debiopharm Group; Diffusion Pharmaceuticals; Duke Street Bio; EcoR1 Capital; Ellipses Pharma; EMD Serono; Entos; F-Star; FoRx Therapeutics; Genesis Therapeutics; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Grey Wolf Therapeutics; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; IDEAYA Biosciences; Idience; Ignyta; ImmuneSensor Therapeutics; IMPAC Medical Systems; Intellisphere; Janssen; Kyn therapeutics; Kyowa Kirin International; Lumanity; MEI Pharma; Merck; Mereo BioPharma; Merit, Inc.; Monte Rosa Therapeutics; Natera; Nested Therapeutics; Nexys Therapeutics; Nimbus Therapeutics; Novocure; Odyssey Therapeutics; OncoSec; Ono Pharmaceutical; Onxeo; Oregon Health & Science University (OHSU); PanAngium Therapeutics; Pegascy; PER; Pfizer; Piper Sandler; Pliant; Prelude Therapeutics; ProLynx; Protai; Radiopharm Theranostics; Repare Therapeutics; resTORbio; Roche; Ryvu Therapeutics; Sanofi; Schrodinger; SERVIER; Swiss Group for Clinical Cancer Research; Synnovation Therapeutics; Synthis Therapeutics; Tango Therapeutics; TCG Crossover; TD2; Terns Pharmaceuticals; Terremoto Biosciences; Tessellate Bio; Theragnostics; Thryv Therapeutics; Tolremo; Tome Biosciences; Trevarx Biomedical; Varian Medical Systems; Veeva Systems; Versant Health; Vibliome Therapeutics; Voronoi Health Analytics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boundless Bio; Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); CPRIT; Cyteir (Inst); Department of Defense; EMD Serono (Inst); Exelixis; F-Star (Inst); Forbius (Inst); Genentech (Inst); Gilead Sciences; GlaxoSmithKline (Inst); Golfers Against Cancer; Haihe Biopharma (Inst); IDEAYA Biosciences; ImmuneSensor Therapeutics (Inst); InSilico Medicine; Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); NIH/NCI; Novartis (Inst); Pfizer (Inst); Pliant; Prelude Therapeutics; Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche; Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Synnovation Therapeutics; Tango Therapeutics; Tesaro (Inst); V Foundation; Vivace Therapeutics (Inst); Zenith Epigenetics (Inst); Zentalis
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Consulting or Advisory Role - Celularity; Guardant Health; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
 
Wade Iams
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb/Pfizer; Catalyst Pharmaceuticals; Daiichi Sankyo; Elevation Oncology; EMD Serono; Genentech; Gilead Sciences; Guardant Health; Jazz Pharmaceuticals; Johnson & Johnson; Merus; Novocure; Sanofi; Takeda; Tempus
Speakers' Bureau - Amgen; Jazz Pharmaceuticals; Novocure
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; Bristol-Myers Squibb; Ellipses Pharma; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); Hemavant Sciences (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - Bristol-Myers Squibb
 
Tatiana Hernandez Guerrero
No Relationships to Disclose
 
Guzman Alonso
Consulting or Advisory Role - Boehringer Ingelheim; Ellipses Pharma
 
Carlos Gomez-Roca
Honoraria - PharmaMar; PSAD
Consulting or Advisory Role - Ellipses Pharma; Macomics
Research Funding - Amgen (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
(OPTIONAL) Uncompensated Relationships - ESMO; FITC; Oncodistinct
 
Sophie Postel-Vinay
Consulting or Advisory Role - Amgen (Inst); Daiichi Sankyo (Inst); EPICs therapeutics
Research Funding - Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo/Lilly (Inst); GlaxoSmithKline/Tesaro (Inst); Roche/imCORE (Inst)
 
Fabian Acker
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo; IQVIA; Novartis; Novocure
Consulting or Advisory Role - Daiichi Sankyo; Novartis; Novocure
Speakers' Bureau - Amgen; AstraZeneca
Research Funding - AstraZeneca (Inst)
Expert Testimony - Daiichi Sankyo; IQVIA
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo
 
Anna Minchom
Honoraria - GlaxoSmithKline; Janssen; Merck; Seagen; Takeda
Consulting or Advisory Role - AstraZeneca; Faron Pharmaceuticals; GlaxoSmithKline; Immutep; Janssen Oncology; Merck; MSD; Pfizer
Research Funding - Astex Pharmaceuticals (Inst); Merck (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Natasha Leighl
Research Funding - AstraZeneca Canada (Inst); GlaxoSmithKline Canada (Inst); Guardant Health (Inst); Inivata/NeoGenomics (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Guardant Health; Janssen; MSD Oncology; Roche; Sanofi
 
William Novotny
Employment - Prelude Therapeutics
Leadership - Prelude Therapeutics
Stock and Other Ownership Interests - Prelude Therapeutics
Travel, Accommodations, Expenses - Prelude Therapeutics
 
Chris Tankersley
Employment - Amgen (I); Prelude Therapeutics
Stock and Other Ownership Interests - Amgen (I); Prelude Therapeutics
Travel, Accommodations, Expenses - Amgen; Prelude Therapeutics
 
Megan Henry
Employment - Prelude Therapeutics
Travel, Accommodations, Expenses - Prelude Therapeutics
 
Sunhee Ro
Employment - Prelude Therapeutics; Sierra Oncology
Stock and Other Ownership Interests - Amgen
Research Funding - Prelude Therapeutics; Sierra Oncology
 
Michael Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
John Bridgewater
Honoraria - Incyte; SERVIER
Consulting or Advisory Role - AstraZeneca; Basilea; Bayer; Incyte; Merck Serono; Merck Serono; Roche; SERVIER; Taiho Oncology
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene
Research Funding - Amgen; Incyte (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Medarex; Merck Serono; MSD Oncology; SERVIER